Video

Dr. Modest on Study of Surgical Intervention in CRC

Dominik P. Modest, MD, University of Munich, discusses an evaluation of resection in patients with metastatic colorectal cancer.

Dominik P. Modest, MD, University of Munich, discusses an evaluation of resection in patients with metastatic colorectal cancer (mCRC).

In a central evaluation for surgical treatment options in the FIRE-3 study results, a panel of 8 surgeons and 3 medical oncologists served as reviewers of 448 patients, defining resectability as at least 50% of the reviewers recommending surgical intervention.

Findings showed that roughly 20% of the population would have been a candidate for surgical intervention and at best response, it was a little more than 50%, says Modest.

Related Videos
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System